Clinical Trial

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Completed
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to characterize the safety profile of sotorasib.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-20; most recent amendment 2026-04-01.
Status change: Recruiting → Completed 2026-04-01
Status change: Not Yet Recruiting → Recruiting 2025-09-10
Trial Details
NCT Number NCT07143513
Lead Sponsor Amgen
Conditions Non-Small Cell Lung Cancer
Enrollment 102 participants
Start Date 2025-08-11
Primary Completion 2025-12-07 (estimated)
Study Completion 2025-12-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-07